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Aims Although dyspnoea is the most common cause of admission for acute heart failure (AHF), more needs to be known
about its clinical course and prognostic signiﬁcance.
Methods
and results
The Pre-RELAX-AHF studyrandomized 232 subjects with AHF to placebo or four doses of relaxin and evaluated early
(6–24 h Likert scale) and persistent [change in visual analogue scale area under the curve (VAS AUC) through Day 5]
dyspnoea relief. Worsening heart failure (WHF) was deﬁned as worsening AHF signs and symptoms requiring
additional therapy. Patients werefollowed until Day 180. Early dyspnoea relief was observed in only 25% of all patients,
and VAS AUC at 5 days was 45% over baseline values in all patients (32% placebo; 50% all relaxin-treated patients).
Worsening heart failure to Day 5 was observed in 16% of all patients (21% placebo; 14% relaxin). Lack of persistent
dyspnoea relief and WHF were associated with a longer length of initial hospital stay and worse 60-day outcomes.
Conclusion Dyspnoea relief in patients admitted with AHF is often incomplete, and many may show WHF after the initial stabiliz-
ation. Both lack of persistent dyspnoea relief and in-hospital WHF predict a longer length of stay and worse outcome.
-----------------------------------------------------------------------------------------------------------------------------------------------------------
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Introduction
Although acute heart failure (AHF) remains the most common
cause of hospitalization in people .65 years of age,
1–4 its treat-
ment has changed minimally in the last few decades, with no
new therapies approved and accepted globally in over 25 years.
Dyspnoea is the principal cause of hospitalization for patients
with AHF and is often associated with signs of ﬂuid overload,
including pulmonary and/or peripheral congestion.
2,5–7 Recent
AHF studies have shown that moderate to marked relief of dys-
pnoea occurs in only a relatively small percentage of patients
(40–60%) in the ﬁrst days after admission.
8–13 Furthermore,
depending on the deﬁnition, 10–20% of patients may develop
recurrent symptoms and signs of heart failure [worsening heart
failure (WHF)]
14–16 or die during the ﬁrst few days from admis-
sion. These disappointing results are observed even when
guideline-recommended therapies are fully implemented. More-
over, new agents for the treatment of AHF have not shown con-
vincing beneﬁts.
5–7,17,18 Although some AHF therapies have
been associated with minimal or moderate improvement in dys-
pnoea, the absence of robust safety data have either prevented
their regulatory approval or limited their use. Hence, rapid and
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ward effects on outcomes remains an important and unmet goal of
AHF therapy.
The Preliminary study of RELAX in Acute Heart Failure
(Pre-RELAX-AHF) assessed the efﬁcacy and safety of the naturally
occurring peptide relaxin, a vasodilator with multiple potentially
beneﬁcial effects, in patients hospitalized with AHF, mild to mod-
erate renal dysfunction, signs of ﬂuid overload, and increased
plasma concentrations of brain natriuretic peptide (BNP) or
N-terminal pro brain natriuretic peptide (NT-proBNP).
19 Relief
of dyspnoea, death, or WHF during hospitalization were prospec-
tively deﬁned and assessed in this trial. The purpose of the current
analysis was to characterize in depth the extent and time course of
dyspnoea relief and assess its association with other clinical out-
comes in patients with AHF.
Methods
Patients
Methods and results of Pre-RELAX-AHF have been detailed pre-
viously.
19 Brieﬂy, this study enroled patients aged ≥18 years who
were within 16 h of presentation to hospital for AHF, with a systolic
blood pressure (BP) .125 mmHg at screening and impaired renal
function [deﬁned as an estimated glomerular ﬁltration rate (eGFR)
of 30–75 mL/min/1.73 m
2]. Acute heart failure was deﬁned by the
presence of dyspnoea at rest or with minimal exertion, pulmonary
congestion on chest radiograph, and increased natriuretic peptide con-
centrations (BNP ≥350 pg/mL or NT-proBNP ≥1400 pg/mL) with the
administration of at least 40 mg of intravenous furosemide (or equival-
ent loop diuretic) between presentation and screening. A systolic BP
.125 mmHg was chosen as an inclusion criterion as likely associated
with the best beneﬁt to risk ratio for a study drug such as relaxin
having vasodilating and, potentially, hypotensive effects and adminis-
tered at a wide range of doses in the phase II Pre-RELAX-AHF
trial.
1,2,20
Patients were randomized within 16 h of presentation to receive
placebo or 10, 30, 100, or 250 mg/kg/24 h of relaxin. Study medication
was given as a continuous intravenous (IV) infusion over 48 h. Patients
were allowed to receive other therapies at the treating physician’s dis-
cretion, anytime after administration was initiated. At the time of ran-
domization, IV nitrates were only allowed if the patient’s systolic BP
was .150 mmHg at screening. The Pre-RELAX-AHF study was
approved by the appropriate regulatory authorities and Ethics Com-
mittees prior to patient enrolment, and written informed consent
was obtained from each patient before study-speciﬁc procedures
were performed.
Assessment of dyspnoea and worsening heart
failure
Patients assessed their dyspnoea at baseline and then at 6, 12, and 24 h
from randomization and then daily to Day 5, and then at Day 14, using
patient-reported assessment tools, which included the following two
main measures. (i) Absolute dyspnoea severity, assessed at each time
point on a visual analogue scale (VAS) using a 100 mm vertical line,
upon which patients were required to draw a horizontal line rating
their breathing, with 100 representing the ‘best imaginable health
state’ and zero ‘the worst imaginable health state’. (ii) Additionally,
relative changes in dyspnoea were captured using a 7-point Likert
scale by which patients were required to rate their breathing as
being markedly, moderately, or minimally better; no change; or mini-
mally, moderately, or markedly worse compared with baseline.
Dyspnoea assessment was done at all-time points with the patient
lying on the bed, with the head of the bed elevated to 30 degrees,
legs on the bed, and oxygen withdrawn for 5 min. If the patient
could not tolerate the position or being taken off oxygen for 5 min,
these measures were discontinued, and the patient was requested to
complete the dyspnoea assessment describing how they felt at the
time the oxygen was withdrawn. Dyspnoea questionnaires were trans-
lated into all languages by certiﬁed translators.
After the assessment of dyspnoea, physicians were requested to
perform, on a daily basis, additional clinical evaluations including assess-
ment of orthopnoea, dyspnoea on exertion, as well as congestion by
assessing jugular venous pressure (JVP), pulmonary rales, peripheral
oedema, and body weight. After these clinical assessments, the phys-
ician was requested to specify whether the patient had worsening
symptoms and/or signs of heart failure requiring the increase or
re-institution of intravenous or mechanical therapy for heart failure
(WHF). Physicians were instructed that either a pulmonary oedema
event during the preceding 24 h or a gradual deterioration, both
requiring addition of IV or mechanical therapy for heart failure,
should be reported as WHF. On the other hand, addition of IV
therapy for other reasons, such as control of hypertension or
enhanced diuresis in the absence of worsening symptoms or signs of
heart failure, was not considered WHF. Worsening heart failure
through Day 5 was examined in the current analysis. Blood samples
for central laboratory analysis, including serum creatinine, were col-
lected daily through Day 5 and at Day 14.
Deﬁnitions of early dyspnoea relief and
persistent dyspnoea relief
Early dyspnoea relief was deﬁned as a moderately or markedly better
dyspnoea assessed by the Likert scale at 6,12, and 24 h (all three time
points) from study drug initiation.
Persistent dyspnoea relief was assessed using the VAS over 5 days.
The area under the curve (AUC) representing the change in VAS
score from baseline over time was computed from baseline to Day
5 for each patient by the trapezoidal rule. For the purposes of exam-
ining baseline characteristics and associations with other heart failure
signs and symptoms, patients were classiﬁed as having persistent dys-
pnoea relief if their VAS AUC fell into the upper tertile of the
overall distribution. For modelling purposes, the VAS AUC was exam-
ined as a continuous variable.
Follow-up
Patients were followed to Days 60 and 180 by telephone calls. At Day
60, all rehospitalizations and deaths were collected and the cause for
each reported. At Day 180, all deaths between Day 60 and Day 180
were reported including cause of death as determined by the
investigator.
Statistical methods
All data are shown as mean + standard deviation unless otherwise
speciﬁed. Generally, groups were compared using t-tests for continu-
ous variables and x
2 tests for dichotomous variables. Univariable and
multivariable logistic regression models were used to describe poten-
tial predictors of early dyspnoea relief and WHF; linear regression was
used to examine potential predictors of dyspnoea VAS AUC. Variables
considered were those shown in larger databases to be important
prognostic factors in AHF.
4,21–23,. The last observation was carried
forward for missing dyspnoea scores, except that the worst possible
Dyspnoea in acute heart failure 1131score was carried forward from the time of death or WHF onset.
Unimputed scores were used to evaluate correlations between dys-
pnoea changes and changes in other heart failure symptoms and
signs. Spearman’s rank correlation coefﬁcients are presented, with
P-values for the t-test of no correlation. Length of stay was imputed
as the maximum length of stay plus 1 Day (33 days) for patients
who died during the initial hospital admission. Linear regression was
used to examine VAS AUC as a predictor of length of stay and days
alive out of hospital. Kaplan–Meier estimates of the risks of death or
the composite of death or rehospitalization are presented. The time
to event was censored at last patient contact for patients without
the event of interest. Survival analyses were restricted to patients
with event times after Day 1 (where baseline was Day 0) for the analy-
sis of early dyspnoea relief and to patients with event times after Day 5
for analyses of VAS AUC and WHF. Hazard ratios were estimated
using Cox proportional hazards regression. Results for the four
relaxin dose groups combined as compared with placebo are also
described. No adjustment for multiple comparisons was made. Two-
sided P , 0.05 was regarded as statistically signiﬁcant.
Results
Rates of dyspnoea improvement
Of the 234 patients randomized at 54 centres in 8 countries, 232
had assessments of dyspnoea that allowed classiﬁcation of early
and persistent dyspnoea improvement. A total of 229 randomized
patients were treated with relaxin or placebo and were included in
treatment group for comparisons. Overall, moderately or mark-
edly better dyspnoea was observed at 6, 12, and 24 h (early dys-
pnoea relief) in 25% of patients (23% on placebo and 26%
assigned to relaxin at all doses combined). Overall only 70% of
patients had moderately or markedly better dyspnoea at Day 14
(the last assessment in the study).
By Day 5, VAS increased from an average baseline of 42.3+
20.1 mm, by 14.3+30.6 mm in the placebo group vs. 23.3+
29.8 mm in the overall relaxin group. The mean dyspnoea VAS
AUC from baseline to Day 5 was 1679+2556 mm h in placebo
and 2412+2721 mmh in all relaxin-treated patients. These
AUCs correspond to average relative improvements from baseline
over the 5 days of 31.7% in placebo and 50.0% in all relaxin patients.
The cumulative rate of WHF was 1% at 6 h, 4% at 12 h, 8% at
24 h, and 16% at Day 5. The rate of WHF to Day 5 was 21% in
placebo and 14% in the combined active treatment groups.
Association with baseline characteristics
Baseline characteristics of patients with and without early or sus-
tained dyspnoea relief or with WHF are presented in Table 1.
Early dyspnoea relief was associated with a greater proportion of
patients with high-BNP or NT-proBNP level, a lower mean respir-
atory rate, and a higher mean systolic BP at baseline. Persistent
dyspnoea relief, assessed by VAS AUC, was also associated with
a lower mean baseline respiratory rate. In contrast, absence of
WHF was associated with lower mean baseline blood urea
nitrogen (BUN) and serum creatinine levels as well higher mean
serum sodium at baseline.
Univariable and multivariable models of the association of base-
line characteristics with early dyspnoea relief, dyspnoea VAS AUC,
and WHF are shown in Table 2. All the variables listed in this table
were entered into the multivariable model. Few baseline character-
istics were related to dyspnoea relief in both univariable and multi-
variable analyses. Early dyspnoea relief was associated with baseline
systolic BP, and both early dyspnoea relief and dyspnoea VAS AUC
were signiﬁcantly related to baseline respiratory rate, after multi-
variable adjustment. Worsening heart failure remained correlated
with lower sodium at baseline.
Association with changes in other signs
and symptoms and treatment
Favourable changes in dyspnoea were signiﬁcantly correlated with
favourable changes in other heart failure signs and symptoms,
including general well-being, orthopnoea, dyspnoea on exertion,
and oedema (Table 3). Dyspnoea changes were less consistently
correlated with changes in rales, JVP, and weight. Prescription
rates for angiotensin-converting enzyme-inhibitors (ACE-I), angio-
tensin receptor blocker (ARBs), and beta-blockers at randomiz-
ation were similar for patients who did and did not have
dyspnoea relief (Table 4). Patients with dyspnoea relief and lack
of WHF were more likely to receive ACE-I, ARBs, and beta-
blockers at discharge and Day 14, although this did not reach stat-
istical signiﬁcance.
Association with short- and
intermediate-term outcomes
Associations of early dyspnoea relief, dyspnoea VAS AUC, and
WHF with length of stay and days alive and out of hospital to
Day 60 are given in Table 5, and associations with rates of
re-admission for heart or renal failure or cardiovascular death to
Day 60 and cardiovascular death to Day 180 are presented in
Table 6. Patients with lack of dyspnoea relief and WHF had
trends, sometimes reaching statistical signiﬁcance, for a longer
length of stay, fewer days alive, and out of hospital and higher car-
diovascular mortality.
Discussion
The present analysis of data from Pre-RELAX-AHF shows that
early and persistent relief of dyspnoea are uncommon in these
patients with AHF. About three-quarters of the patients studied
did not have early dyspnoea relief, whereas persistent dyspnoea
relief at Day 5 in the placebo group was limited to  32% relative
improvement over baseline. In addition, approximately a quarter of
our patients developed recurrent symptoms and signs of heart
failure during the initial hospitalization, necessitating increases or
initiation of IV or mechanical therapy for heart failure (WHF). Dys-
pnoea improvement was, to some extent, predicted by higher sys-
tolic BP at baseline and a lower baseline respiratory rate. Freedom
from WHF was predicted by a better renal function and higher
serum sodium at baseline. Administration of relaxin was associated
with early and more persistent dyspnoea relief and lower likeli-
hood of WHF. Lack of dyspnoea relief and WHF tended to be
associated with longer length of stay and poorer long-term
outcome. However, these data need to be conﬁrmed in larger
study groups.
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Table 1 Baseline characteristics of patients with and without early and persistent dyspnoea relief and worsening heart failure
Early dyspnoea relief Persistent dyspnoea relief Worsening heart failure
Baseline characteristic Yes (n 5 58) No (n 5 174) P Upper tertile (n 5 79) Lower 2 tertiles (n 5 153) P No (n 5 196) Yes (n 5 36) P
Age (years) 71 + 97 0 + 11 0.67 72 + 10 70 + 11 0.16 70 + 11 73 + 8 0.11
Male (%) 48 58 0.19 52 57 0.41 55 58 0.72
Body weight (kg) 83 + 17 80 + 17 0.30 79 + 18 82 + 17 0.42 82 + 17 78 + 16 0.27
COPD (%) 19 16 0.61 19 16 0.52 16 19 0.65
Diabetes (%) 50 41 0.26 53 39 0.05 45 39 0.53
Hypertension (%) 93 83 0.07 89 84 0.37 87 81 0.33
Ischaemic heart disease (%) 59 73 0.03 70 70 0.99 70 69 0.97
Peripheral vascular disease (%) 14 13 0.82 16 11 0.25 11 22 0.07
Stroke (%) 19 15 0.54 19 15 0.44 16 19 0.59
Systolic BP (mmHg) 151 + 18 143 + 17 ,0.01 147 + 15 144 + 19 0.29 146 + 17 144 + 20 0.52
Diastolic BP (mmHg) 84 + 12 81 + 11 0.11 81 + 11 83 + 12 0.42 82 + 12 82 + 11 0.88
Heart rate/min 83 + 15 82 + 15 0.68 79 + 12 84 + 16 0.03 82 + 15 82 + 15 0.96
Atrial ﬁbrillation (%) 43 49 0.43 40 51 0.12 47 53 0.50
Respiratory rate/min 22+32 3 +3 ,0.01 22+32 3 +4 ,0.01 23+32 4 +4 0.27
Haemoglobin (g/dL) 13 + 21 3 + 2 0.24 13 + 21 3 + 2 0.17 13 + 21 3 + 2 0.15
BUN (mg/dL) 27 + 10 27 + 12 0.79 26 + 11 28 + 12 0.26 26 + 11 31 + 13 0.02
Serum creatinine (mg/dL) 1.4 + 0.5 1.3 + 0.5 0.29 1.3 + 0.5 1.3 + 0.5 0.41 1.3 + 0.5 1.5 + 0.5 0.03
eGFR, screening (mL/min/1.73 m
2)5 3 + 16 54 + 17 0.83 54 + 20 53 + 15 0.51 54 + 17 50 + 14 0.15
Sodium (mmol/L) 141 + 4 140 + 4 0.49 140 + 3 141 + 4 0.34 141 + 31 3 9 + 5 0.01
White blood cell count (×10
9/L) 8.3 + 2.6 8.7 + 3.3 0.53 8.6 + 3.3 8.6 + 3.1 0.93 8.5 + 3.0 9.1 + 3.7 0.32
Lymphocytes ,13% (%) 71 71 0.99 60 76 0.02 73 59 0.12
BNP .500 or NT-proBNP .2000 pg/mL (%) 86 70 0.02 79 72 0.22 72 83 0.17
Troponin .0.10 ng/mL (%) 16 17 0.84 21 15 0.22 17 17 0.98
ACE-inhibitor or ARB (%) 67 65 0.75 67 65 0.72 65 69 0.59
Nitrates (%) 24 20 0.52 22 21 0.91 21 22 0.86
Hydralazine (%) 5 1 0.07 4 1 0.22 3 0 0.33
b-blocker (%) 57 56 0.88 59 54 0.45 56 58 0.76
Calcium-channel blocker (%) 12 16 0.52 20 12 0.08 15 14 0.89
Aldosterone inhibitor (%) 21 36 0.03 19 39 ,0.01 32 33 0.89
Digoxin (%) 19 21 0.71 10 26 ,0.01 18 33 0.04
Early dyspnoea relief was deﬁned as a markedor moderate improvement in dyspnoea by the Likert scale at6, 12, and 24 h from randomization. Persistent dyspnoea relief wasmeasuredon the basis of the changes in the AUC of VAS assessed at
5 days from randomization.
BP, blood pressure; BUN, blood urea nitrogen; COPD, Chronic Pulmonary Obstructive Disease; eGFR, estimated glomerular ﬁltration rate.
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Table 2 Univariable and multivariable regression analyses of predictors of early dyspnoea relief, dyspnoea visual analogue scale area under the curve to Day 5, and
worsening heart failure to Day 5
Early dyspnoea relief Dyspnoea VAS AUC to Day 5 Worsening heart failure
Univariable model Multivariable model Univariable model Multivariable model Univariable model Multivariable model
SD OR (95%CI) P OR (95%CI) P Mean change
(SE)
P Mean change
(SE)
P OR (95%CI) P OR (95%CI) P
Age 10.47 1.07 (0.79–1.44) 0.67 1.44 (0.90–2.29) 0.13 113 (177) 0.53 128 (229) 0.58 1.38 (0.93–2.04) 0.11 1.15 (0.70–0 1.87) 0.57
Male 0.67 (0.37–1.22) 0.20 0.36 (0.14–0.94) 0.04 2572 (354) 0.11 2403 (497) 0.42 1.14 (0.56–2.34) 0.72 0.85 (0.30–2.40) 0.76
History of myocardial infarction 0.77 (0.42–1.40) 0.38 0.96 (0.42–2.21) 0.93 237 (356) 0.92 265 (420) 0.53 0.74 (0.36–1.51) 0.41 0.62 (0.26–1.51) 0.29
Pulse 14.96 1.06 (0.79–1.43) 0.68 1.04 (0.70–1.55) 0.85 2161 (177) 0.36 2194 (211) 0.36 0.99 (0.69–1.42) 0.96 1.03 (0.67–1.60) 0.88
Respiratory rate 3.59 0.59 (0.43–0.81) ,0.01 0.44 (0.29–0.67) ,0.01 2531 (174) 0.0026 2697 (204) ,0.01 1.23 (0.85–1.76) 0.27 1.58 (1.02–2.45) 0.04
Systolic blood pressure 17.87 1.52 (1.14–2.03) ,0.01 1.73 (1.14–2.64) 0.01 183 (177) 0.30 127 (226) 0.57 0.88 (0.61–1.28) 0.52 0.90 (0.56–1.42) 0.64
Sodium 3.92 1.12 (0.82–1.52) 0.49 1.23 (0.79–1.92) 0.36 161 (178) 0.37 242 (208) 0.25 0.66 (0.47–0.92) 0.02 0.63 (0.43–0.94) 0.02
BUN 11.46 0.96 (0.71–1.30) 0.79 0.76 (0.40–1.42) 0.38 2301 (177) 0.09 2359 (315) 0.26 1.46 (1.05–2.03) 0.03 1.20 (0.64–2.24) 0.57
Creatinine 0.47 1.17 (0.87–1.56) 0.29 1.48 (0.81–2.72) 0.20 2215 (173) 0.22 75 (323) 0.82 1.42 (1.02–1.96) 0.04 1.32 (0.71–2.46) 0.39
Haemoglobin at baseline 1.83 1.22 (0.87–1.70) 0.24 1.68 (1.06–2.65) 0.03 17 (190) 0.93 258 (224) 0.80 0.76 (0.53–1.10) 0.15 0.84 (0.54–1.30) 0.44
WBC-lymphocytes%,13% 1.00 (0.49–2.06) 0.99 0.86 (0.36–2.04) 0.73 28 (424) 0.95 273 (458) 0.87 0.54 (0.25–1.19) 0.12 0.62 (0.25–1.54) 0.30
Troponin positive 0.92 (0.41–2.08) 0.84 1.20 (0.45–3.20) 0.72 317 (481) 0.51 536 (509) 0.29 1.02 (0.39–2.65) 0.98 0.67 (0.22–2.03) 0.48
Admission BNP .500 or NT-proBNP
.2000 pg/mL
2.66 (1.18–6.01) 0.02 1.59 (0.54–4.63) 0.40 21.8 (404.3) 1.00 51 (486) 0.91 1.90 (0.75–4.82) 0.18 1.60 (0.55–4.67) 0.39
ORs andmean changes presented are fora standard deviation increase incontinuous predictors and fora 1-unit change for dichotomous predictors from logistic regression models forearly dyspnoea relief and worsening heart failureand from
linear regression models for dyspnoea VAS AUC.
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4Relief from dyspnoea and worsening heart
failure in patients admitted for acute
heart failure
Symptoms of heart failure, usually dyspnoea, are the main cause of
hospitalization in AHF. These symptoms are so disabling that
patients with advanced heart failure have professed acceptance
of an increased risk of death for some improvement in symp-
toms.
24 The importance of dyspnoea is recognized by regulatory
agencies and accepted as an important endpoint required for regis-
tration trials of new AHF medical treatments, provided there is suf-
ﬁcient evidence of safety.
25,26 Improved standardization of
dyspnoea measurement has been proposed
27 and adopted in clini-
cal trials, including in Pre-RELAX-AHF.
19
Rates of early and persistent dyspnoea relief were surprisingly
low in our study. This ﬁnding is at odds with previous trials
where higher rates were reported. Using the Likert scale (similar
to the one used in the current study),  45% of patients enroled
in the placebo arm of the VMAC study had moderate or marked
improvement in dyspnoea by 3 h after enrolment.
5 Similar pro-
portions (40–60%) of patients with improved dyspnoea were
observed in the placebo arm of the REVIVE study at 6 h
17 and in
the Efﬁcacy of Vasopressin Antagonism in Heart Failure
Outcome Study with Tolvaptan (EVEREST).
7,28 Using the VAS in
VERITAS,
6 major improvements in dyspnoea were observed at 3
and 24 h, surpassing those observed in the present study at Day
5. The lower proportion of patients with an early improvement
in dyspnoea and the smaller improvements to Day 5 in the
present study cannot be ascribed to the inclusion of patients
known to be refractory to standard treatment, since we included
only patients within 16 h from presentation (median 6 h).
19 We
do not think that our ﬁndings can be ascribed to the demographic
characteristics of our study group, as they were similar to those of
previous trials, but, rather, to the enrolment criteria of
Pre-RELAX-AHF. These included the need of IV diuretic therapy,
mild to moderate renal dysfunction, signs of congestion at chest
X-ray, and, most important, elevated natriuretic peptide plasma
levels. These criteria allow the exclusion of patients with non-
cardiac causes of symptoms as well as the enrolment of patients
with more severe symptoms and worse prognosis.
4,10 Thus, our
use of objective and more strict inclusion criteria may explain
both the lower rate of dyspnoea relief as well as the unfavourable
prognosis of our patients. Lastly, with respect to the comparison
with EVEREST, it must also be noted that this trial included only
patients with low left ventricular ejection fraction, whereas we
included patients independently from left ventricular ejection frac-
tion (more than half of our patients had a left ventricular ejection
fraction .40%) and their history of heart failure.
In agreement with previous studies,
14,15 WHF during initial
hospitalization (to Day 5 in this study) was observed in about
one-ﬁfth of patients on placebo. This ﬁnding emphasizes the
high chance of relapse of AHF, with many patients worsening
after an initial improvement both in hospital (our deﬁnition of
WHF) and after discharge (leading to re-admissions). Overall,
only a minority of the patients enroled in our study had a
‘benign’ course with early dyspnoea relief and no recurrence of
heart failure.
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Dyspnoea in acute heart failure 1135Determinants of relief of dyspnoea and
worsening heart failure
Few variables predicted relief of dyspnoea in our study. This lack of
association is consistent with our limited knowledge of the factors
associated with this event.
29 More research is needed in larger
databases to establish which factors predict dyspnoea relief in
AHF. In the present study, dyspnoea relief was related to a
higher systolic BP and a lower respiratory rate at baseline, with
both variables likely consistent with a lower severity of cardiac dys-
function at baseline. Worsening heart failure was predicted by
hyponatraemia and kidney dysfunction. These variables have
been associated with worse outcomes in previous studies,
4,21,30
consistent with our ﬁndings of an important predictive power of
symptoms and WHF for future events.
Assessment of dyspnoea in acute heart
failure
In our study, dyspnoea was measured both by the Likert and the
VAS scales. These two scales differ substantially, both with
regard to the degree of granularity and with regard to how dys-
pnoea is measured, relative to baseline with the Likert scale, and
as an absolute level with the VAS scale. Thus, the VAS scale
measures the absolute severity of symptoms and measures them
also at baseline. In addition, being based on a 100-point scale,
...................................... ............................................... .........................................
...............................................................................................................................................................................
Table 4 Relationships between changes in dyspnoea and medical treatment
Early dyspnoea relief Persistent dyspnoea relief Worsening heart failure
Yes
(n 5 58)
No
(n 5 174)
P Upper
tertile
(n 5 79)
Lower 2
tertiles
(n 5 153)
P No
(n 5 196)
Yes
(n 5 36)
P
ACE-I or ARB (%)
One month prior to
presentation
71 70 0.93 76 67 0.17 69 75 0.50
From presentation up to
randomization
67 65 0.75 67 65 0.72 65 69 0.59
At discharge 84 78 0.30 86 76 0.08 81 72 0.22
At Day 14 83 79 0.57 87 76 0.05 82 69 0.08
Beta-blockers (%)
One month prior to
presentation
64 63.8 0.99 66 63 0.64 64 64 0.99
From presentation up to
randomization
57 55.8 0.88 59 54 0.45 57 58 0.76
At discharge 88 81 0.23 83 82 0.82 85 72 0.07
At Day 14 88 81 0.23 83 82 0.82 85 72 0.07
Total dose of IV loop diuretics
to Day 5—Mean (SD)
150 (330) 177 (271) 0.53 124 (194) 194 (322) 0.04 445 (499) 120 (189) ,0.01
Number of patients receiving IV
dopamine, dobutamine, or
milrinone to Day 5
1 6 0.68
a 1 6 0.43
a 25 ,0.01
a
aFisher’s exact test.
......................................... ..................................................... ...........................................
...............................................................................................................................................................................
Table 5 Relationships between changes in dyspnoea and time in and out of the hospital
Early dyspnoea relief VAS AUC to Day 5 Worsening heart failure
Selected outcome Yes
(n 5 58)
No
(n 5 171)
P Mean change per 117 mmh
increase in AUC
a (SE)
P No
(n 5 193)
Yes
(n 5 36)
P
Length of initial stay 10.5+6.8 11.2+7.1 0.54 20.094 (0.019) ,0.0001 10.1+6.2 15.9+8.9 0.0006
Days alive and out of
hospital to Day 60
45.9+13.4 47.0+11.8 0.56 0.14 (0.034) ,0.0001 48.7+9.4 36.2+18.9 0.0004
a117 mm h corresponds to an average increase of 1 mm on the dyspnoea VAS over 5 days.
M. Metra et al. 1136the VAS may be more sensitive to subtle changes in symptoms. On
the other hand, the Likert scale seems closer to everyday clinical
practice where symptoms are assessed rather roughly and mainly
compared with baseline. The differences between the two
methods explain why the Likert scale was more sensitive to
early changes in symptoms, whereas the VAS was able to show
persistent improvement, even late during the hospitalization. This
was shown in a prospective registry, the Prospective Registry to
Evaluate the Evolution of Measures of Disease Severity in Acute
Heart Failure,
31 and conﬁrmed in Pre-RELAX-AHF.
19
Relation of changes in dyspnoea with
other clinical symptoms and signs
and outcomes
Changes in dyspnoea were correlated with changes in other symp-
toms and clinical signs of AHF in this small database. Our results
are in agreement with data from registries
31 as well as with
post-hoc analyses from EVEREST
28 and the PROTECT pilot
study
32 and suggest that changes in dyspnoea are related to
those in patients’ congestion (both peripheral and central).
Relief of dyspnoea and lack of WHF were associated with
trends, sometimes reaching statistical signiﬁcance, towards
improved outcomes such as shorter length of stay, more days
alive, and out of hospital and lower mortality. These associations
are important since they suggest that relief of dyspnoea and pre-
vention of WHF, beyond being an important treatment goal for
symptom improvement, are also markers of better outcome.
Hence, prevention of in-hospital WHF may become a major goal
of therapy in AHF. Given the lack of association between dyspnoea
relief and baseline characteristics, these data suggest that early
assessment of dyspnoea relief may add important prognostic infor-
mation beyond the information available at the time of admission.
The reasons for the association between dyspnoea relief and
outcomes are likely to be multiple. First, relief of dyspnoea may
be a marker of the relief of congestion and of less severe
disease. However, faster resolution of dyspnoea may also reduce
the need for additional therapies (loop diuretics, intravenous vaso-
dilators, and inotropes) that are aimed at symptom relief, yet may
also have potential adverse effects on outcomes.
33,34 In agreement
with this hypothesis, we observed greater use of known life-saving
medications, such as ACE-I or ARBs, and beta-blockers, in the
patients with dyspnoea relief (Table 3). These numbers are small,
however, and require validation in larger studies.
Effects of relaxin administration
Administration of relaxin was associated with trends towards a
greater likelihood of an improvement in persistent dyspnoea and
prevention of WHF compared with placebo. As previously
described,
19 we have assessed a large range of relaxin doses
(25-fold, starting with 10–250 mg/kg/day). Some of these doses
(especially the lowest and highest) were associated with smaller
effects on dyspnoea relief and WHF. The most effective dose of
relaxin (30 mg/kg/24 h) is being tested for efﬁcacy on early and per-
sistent dyspnoea relief, as well as intermediate-term outcomes, in
the ongoing phase III RELAX-AHF study.
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Dyspnoea in acute heart failure 1137Study limitations
This analysis is hypothesis generating, due to the small number of
patients enroled and of events during follow-up. These small
numbers of patients and events have limited the power of our mul-
tivariable analysis to determine the relation between symptom
changes and outcomes. However, given the lack of association of
baseline characteristics known to affect outcomes in AHF with dys-
pnoea relief, it is likely that these effects are independent.
We chose to assess dyspnoea at Day 5 by the VAS AUC
changes, rather than by the Likert scale, based on our analyses
both from a registry
31 and from the present trial,
19 showing that
VAS is more sensitive to long-term (i.e. 5–7 days from admission)
changes. In contrast, data obtained by the Likert scale tend to
remain stable after the ﬁrst days from admission. Visual analogue
scale area under the curve changes have, however, the limitations
of a continuous variable making it difﬁcult to compare groups of
patients by quantitative measures. We have shown that increases
in VAS score were related with better outcomes, namely, a
shorter duration of hospital stay, more days alive outside of the
hospital, and lower 30-day mortality, but no clinical cut-off can
be provided.
Patients enroled in randomized clinical trials may have differ-
ences compared with those treated in everyday clinical practice.
However, in our study, we used objective criteria for the diagnosis
of AHF (increased natriuretic peptide plasma levels) and its sever-
ity (kidney dysfunction, pulmonary congestion, and elevated
natriuretic peptides), and thus our patients may, actually, be
better selected than in clinical practice when many patients may
have a diagnosis of AHF despite having a non-cardiac cause of
their dyspnoea. On the other hand, Pre-RELAX was restricted
to those patients more likely to beneﬁt from relaxin treatment
(i.e. with high-systolic BP). Thus, our data cannot be extended to
all patients admitted for AHF but only to patients with similar clini-
cal characteristics to those enroled in our study.
Conclusions
Our study shows that the rate of early and persistent dyspnoea
relief in patients with AHF may be low, with only 25% of patients
showing early dyspnoea relief and ,50% relative improvement of
dyspnoea to Day 5. Moreover, 20% of patients may have recurrent
WHF during the ﬁrst 5 days after admission. Lack of dyspnoea
relief and presence of WHF were associated with slower improve-
ment in clinical signs of congestion and worse short- and
intermediate-term outcomes. This suggests that, beyond being
the main measure of AHF related to patients’ symptoms, these
endpoints are also related to prognosis and hence may be
regarded as important and meaningful targets of therapy. The
effects of relaxin administration suggest that a further improve-
ment in symptoms and outcomes with new therapies is possible.
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